Effects of Citicoline on Brain Function and Behavior in Marijuana-Dependent Individuals
|ClinicalTrials.gov Identifier: NCT00158249|
Recruitment Status : Completed
First Posted : September 12, 2005
Results First Posted : October 22, 2014
Last Update Posted : October 22, 2014
The Three Aims of this study are (only studies for Aim 1 were completed)
Measure the impact of citicoline on marihuana use patterns in subjects' individualized natural settings and responses to marihuana challenge using functional brain MRI scans.
Hypothesis - 2 g/day citicoline will produce greater reductions in marihuana use and craving in heavy marihuana users than placebo citicoline over a 8-week treatment period as measured in their natural environments. The same participants will experience greater improved brain activation patterns and an improvement in cognitive functioning compared to placebo controlled subjects.
Measure the effects of citicoline on marihuana absorption and metabolism and determine if these changes parallel changes in subjective and physiological responses in a laboratory setting.
Hypothesis - Chronic (8 weeks) treatment with 2 g/day citicoline will produce increases in subjective and physiological effects of both acute marihuana smoking and placebo marihuana smoking compared to chronic placebo citicoline. Citicoline will have no effect on marihuana pharmacokinetics.
- Measure the effects of citicoline on marijuana-induced cue-induced craving and brain electrical activity (EEG).
Hypothesis - Chronic (8 weeks) treatment with 2 g/day citicoline will reduce objective measures of marijuana cue-reactivity, and subjective reports of craving in response to marihuana cues will also be attenuated compared to chronic placebo citicoline treatment.
|Condition or disease||Intervention/treatment||Phase|
|Marijuana Abuse||Drug: citicoline Drug: placebo||Phase 2|
Marijuana dependence is an important public health problem in the United States, yet still no effective therapies are available. It is unclear how marijuana affects brain function after acute or chronic use. Knowing about the changes in brain function during marijuana dependence would aid in the understanding of the neurobiological basis of marijuana abuse and serve as a foundation for the development of new treatment medications for this disorder. New and improved brain imaging techniques, such as functional MRI (fMRI) and magnetic resonance spectroscopy (MRS), allow the viewing of these subtle, yet important, changes in brain function.
Citicoline is used to treat victims of head trauma and neurodegenerative disorders. It has been found to be effective in reducing cocaine use and craving, and it has no known side effects. It has also been shown to reduce marijuana use. This is likely due to citicoline's ability to reduce insomnia and craving, act as a mild antidepressant, and improve cognitive function. How citicoline reduces drug use may be related to effects on cerebral blood flow and/or brain phospholipid metabolism in the reward areas of the brain.
This study will determine whether citicoline alters marijuana use patterns, reduces craving, and affects brain phospholipids and metabolism in marijuana-dependent people. The outcome of the study could offer important insights into the pathophysiology and course of marijuana dependence. Furthermore, this study's outcome could potentially relate to other drug dependence disorders.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||21 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Investigator, Outcomes Assessor)|
|Official Title:||Cannabis Dependence: Imaging and Medication Development - 1|
|Study Start Date :||September 2009|
|Primary Completion Date :||January 2013|
|Study Completion Date :||October 2014|
Placebo Comparator: placebo
matched for physical appearance
2 gm/day, 8 weeks treatment
- Marijuana Use [ Time Frame: Measured for 8 weeks of treatment ]
- Neurocognitive Function [ Time Frame: Before and after 8 weeks of treatment ]Multiple Source Interference Test (MSIT)
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00158249
|United States, Massachusetts|
|McLean Hospital, Department of Psychiatry|
|Belmont, Massachusetts, United States, 02478 9106|
|Principal Investigator:||Scott E. Lukas, PhD||Mclean Hospital|